ecc0509
Small moleculeexperimental
Clinical trial activity
2 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 7, 2021 (NCT05012423)
Timeline
Indications
Mechanism of action
- Amine oxidase, copper containingINHIBITOR
AOC3 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07288138 | Phase 2 | Dec 15, 2025 | Eccogene Clinical Trials |
| NCT05012423 | Phase 1 | Jul 7, 2021 | Eccanga Pty Ltd, Syneos Health |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Eccanga Pty Ltd | For profit | 1 | 1 | 1 | 2021 |
| Eccogene Clinical Trials | For profit | 1 | 1 | 1 | 2025 |
| Syneos Health | For profit | 1 | 0 | 1 | 2021 |
3 organizations
Page 1 / 1